Cyclacel Pharmaceuticals Inc. said it has reached a deal with the Food and Drug Administration on a design for a late-stage study of a potential cancer treatment and plans to begin patient enrollment before the end of 2010.
Scientists have solved a long-standing mystery of how cells conduct "quality control" to eliminate the toxic effects of a certain kind of error in protein production. The findings may lead to a better understanding of a host of neurodegenerative diseases.
Scientists at Duke University Medical Center, in conjunction with several other groups, have uncovered a gene associated with myopia in Caucasian people from several different regions, including Dutch, British and Australian subjects.
Provectus Pharmaceuticals, Inc., a development-stage oncology and dermatology biopharmaceutical company, announces that data from its Phase 2 PV-10 metastatic melanoma study will be presented at the International Melanoma Research Congress.
Rib-X Pharmaceuticals, Inc., a development-stage antibiotics company with a broad product pipeline based on its innovative discovery platform, announced the presentation of positive preclinical data for radezolid at the Interscience Conference on Antimicrobial Agents and Chemotherapy.
Genzyme Corp. said that it is selling its genetic testing business to Laboratory Corp. of America Holdings for $925 million so it can focus on its core growth areas.
Almost a year after studies showed the diet pill Meridia increases heart attack and stroke risk, U.S. health regulators announced they will consider pulling the Abbott Laboratories' drug off the market.
A range of Web-based tools are bringing automated management to more labs.
Simulation of drug-drug interactions anticipate in vivo outcomes.
Fluorescent assay methods aid GPCR investigation in the discovery and development of therapeutic antibodies.
Pharmacokinetic assays have traditionally been a bottleneck in lead optimization, but a new generation of technologies is increasing the throughput of these critical tests.
TTP LabTech has joined forces with Platypus Technologies to offer automated solutions for studying the migration and invasion profiles of different cell lines using the Acumen eX3 laser scanning microplate cytometer.
Bausch + Lomb, the global eye health company, has named Daniel M. Wechsler as corporate vice president and global president of its Pharmaceuticals business.
French drugmaker Sanofi-Aventis SA is sticking to its original offer of $69 a share to buy U.S. biotech company Genzyme Corp., according to a Sanofi spokesman.
In a phase 3 study, researchers randomly assigned patients to one of three treatment groups: those receiving ipilimumab plus an inactive version of gp 100 (a cancer vaccine); those receiving ipilimumab plus gp 100; and those receiving gp 100 plus ipilimumab placebo.